UNSPSC 51112707: Zeniplatin

This classification denotes a platinum compound with the molecular formula C6H6O4.C5H14N2O2.Pt, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40ZQ0A17IT, chemically known as platinum, (2,2-bis(aminomethyl)-1,3-propanediol-n,n)(1,1-cyclobutanedicarboxylato(2-))-, (sp-4-2)- but more generally known as zeniplatin, which bears US NIH Compound Identifier 60505. European Medicines Agency schedules Zeniplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00146MIG.

UNSPSC 51112707 Zeniplatin is a Commodity code that captures pharmaceutical products procured through state health and human services programs, specifically oncology therapeutics and related specialty pharmaceuticals sourced by state Medicaid and employee health benefit administrators. The code sees solicitation activity primarily from state health agencies and Medicaid programs seeking to establish or optimize procurement pathways for high-cost specialty drugs, including direct-to-manufacturer arrangements that bypass traditional pharmacy benefit managers and group purchasing organizations.

The Texas Health and Human Services Commission posted a Request for Information on March 27, 2026 (response due April 3, 2026) seeking vendor capability information for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an exploratory solicitation designed to evaluate direct contracting models with pharmaceutical manufacturers for self-insured employer and state agency health plans. The RFI targets vendors with prior experience negotiating net pricing models and value-based or outcomes-based agreements outside traditional PBM, GPO, and wholesaler channels. No formal competitive solicitation, award value, or set-aside designations are specified in this preliminary market-intelligence phase; Texas HHS intends to use vendor responses to structure a subsequent formal RFP with binding financial and temporal parameters.